Cover image for Vol. 12 Issue 4

Editorial Board Chairs: Antonello Mai, Rainer Metternich. Assoc. Editors: David Peralta, Scott Williams (Sr)

Impact Factor: 2.98

ISI Journal Citation Reports © Ranking: 2015: 18/59 (Chemistry Medicinal); 77/255 (Pharmacology & Pharmacy)

Online ISSN: 1860-7187

Associated Title(s): Angewandte Chemie International Edition, Chemistry - A European Journal, Chemistry – An Asian Journal, ChemBioChem, Medicinal Research Reviews, Molecular Informatics

February 02, 2011

VIP: BZM055, an Iodinated Radiotracer Candidate for PET and SPECT Imaging of Myelin and FTY720 Brain Distribution

VIP: BZM055, an Iodinated Radiotracer Candidate for PET and SPECT Imaging of Myelin and FTY720 Brain DistributionEmmanuelle Briard*, David Orain, Christian Beerli, Andreas Billich, Markus Streiff, Marc Bigaud, and Yves P. Auberson

FTY720 (fingolimod, Gilenya) is a sphingosine 1-phosphate (S1P) receptor modulator that was approved in September 2010 by the USFDA as a first-line treatment for relapsing forms of multiple sclerosis (MS). There is preclinical evidence that in addition to reducing infiltration of lymphocytes into the central nervous system (CNS), FTY720 may provide additional neuroprotection through modulation of cerebral S1P receptors. To further study the action of FTY720 in the CNS, Emmanuelle Briard, Yves Auberson, and colleagues at the Novartis Institutes for BioMedical Research in Basel (Switzerland) evaluated a series of iodinated FTY720 derivatives that could be used to study the drug's brain distribution in patients using nuclear imaging techniques.

After extensive profiling, they identified 2-iodo-FTY720 (BZM055) as a close mimic of FTY720, having similar physicochemical properties and organ distribution, despite the addition of an iodine atom. They also showed that BZM055 is phosphorylated into its biologically active form at a similar rate to FTY720, retaining an affinity and selectivity for S1P receptors comparable to FTY720-phosphate, as well as similar brain penetration kinetics. [123I]BZM055 is currently being developed as a SPECT tracer for studying the pharmacokinetics and distribution of FTY720 in the human brain. In addition, and since FTY720 has been shown to accumulate in myelin sheaths, this tracer might also prove useful to image myelin in MS patients.

Received November 4, 2010; published online January 30, 2011, DOI: 10.1002/cmdc.201000477.

Your Comment...

[Browse more news]